Clinical Trials Logo

Dense Deposit Disease clinical trials

View clinical trials related to Dense Deposit Disease.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02302755 Withdrawn - Clinical trials for Dense Deposit Disease

TP10 Use in Patients With C3 Glomerulopathy (C3G)

Start date: November 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of repeated TP10 dosing in pediatric and adult patients with C3G and to evaluate the activity of TP10 in pediatric and adult patients with C3G, as measured by the proportion of patients with normalization of serum C3, serum C3 breakdown products, or alternative pathway (AP) complement activity.

NCT ID: NCT00583427 Withdrawn - Clinical trials for Dense Deposit Disease

Sulodexide Treatment in Patients With Dense Deposit Disease

Start date: December 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to see if a medicine called Sulodexide will help prevent or slow down the progression of Membranoproliferative Glomerulonephritis type II/Dense Deposit Disease. Sulodexide is not yet FDA approved and has not been studied in children. Study aim/hypotheses: to measure the efficacy of Sulodexide treatment in patients with the above disease/s.